Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DTC advertising bill

This article was originally published in The Gray Sheet

Executive Summary

House bill introduced May 22 would place a three-year moratorium on direct-to-consumer advertising of devices and drugs, with the exception of products for which HHS affirms a public health need. Sponsored by Reps. Rosa DeLauro, D-Conn., and Jo Ann Emerson, R-Mo, H.R. 6151 would require device and drug firms to distribute corrective materials and pay civil penalties if they violated the moratorium. "Public relations should never trump public health," DeLauro said. FDA is facing increasing pressure to clamp down on excessive ads, including a December petition from the Consumers Union seeking additional warning statements (1"The Gray Sheet" Feb. 18, 2008, p. 5). Separately, an article by two cardiologists in the New England Journal of Medicine earlier this month had criticized Johnson & Johnson/Cordis' ad campaign for its Cypher drug-eluting stent (2"The Gray Sheet" May 19, 2008, p. 14)

You may also be interested in...

Cardiologists Critique Consumer TV Advertising For Interventional Devices

Direct-to-consumer television advertising of surgical devices raises more troubling questions than do many prominent pharmaceutical DTC ads, two cardiologists argue in an article posted on the New England Journal of Medicine Web site last week

Device Firms Under Pressure To Add More Warnings To DTC Ads

Public pressure is increasing on device firms, especially orthopedic implant manufacturers, to include more detailed risk information about their products in direct-to-consumer broadcast advertisements

Second Judge Rejects Constitutional Challenges To Medicare Price Negotiation Program

Delaware district judge rules against AstraZeneca’s claim the IRA violates its due process rights, echoing findings made by Ohio district judge in Chamber of Commerce’s suit. Only other IRA ruling to date dismissed PhRMA’s complaint on procedural grounds without addressing the merits.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts